Iovance Biotherapeutics Inc. (IOVA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.02 (-5.42% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IOVA ranks #298 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IOVA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.3%, and ROIC of -35.0%. By comparison, TARS (Tarsus Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -24.1%, cap $3.61B) and RLAY (Relay Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.79B). Among the 5-stock peer group, IOVA leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per IOVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425205), Iovance Biotherapeutics Inc. generated $263.5M in revenue (+60.6% YoY), -$391.0M in net income, and -$336.2M in free cash flow against $913.2M in total assets and $96.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 7.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 31.8 (OVERSOLD (<32))
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While IOVA currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.43) and Max Pain ($8.42) forces dealer call-delta covering toward $16.14.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Iovance Biotherapeutics Inc. (IOVA) dropped -5.42% to $8.02, trading at 46% of its 52-week range ($1.76 – $15.37). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
AstraZeneca emphasized ADC combinations, cell therapies and internally developed cancer vaccines as key oncology priorities.
Key TakeawaysIovance shares fell another 11% today after Baird cut its price target to $9 from $11, a day after a 35% drop on updated lung cancer data. The trial’s 24.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IOVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IOVA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Iovance Biotherapeutics Inc. (IOVA) ranks #298 by composite RQD confidence (47/100, grade D) and #186 by equity capitalization ($3.63B). Within this direct 5-issuer industry benchmark cohort, IOVA leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. TARS currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with IOVA at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IOVA
ACTIVE
Iovance Biotherapeutics Inc. | D | 47/100 | — | 34.3% | -35.0% | -5.42% | $3.63B | Benchmark Subject |
| TARS Tarsus Pharmaceuticals Inc. | D | 50/100 | — | — | -24.1% | -2.04% | $3.61B | /tars-vs-iova → |
| RLAY Relay Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -5.83% | $3.79B | /rlay-vs-iova → |
| ADPT Adaptive Biotechnologies Corporation | D | 48/100 | — | 74.2% | -12.5% | -5.93% | $4.00B | /adpt-vs-iova → |
| DNLI Denali Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -0.42% | $3.01B | /dnli-vs-iova → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Iovance Biotherapeutics Inc. (IOVA) reported GAAP revenue of $263.5M (+60.6% vs. FY2024 revenue of $164.1M , and +22061.6% cumulative change since FY2023) , GAAP net income of -$391.0M, operating cash flow of -$302.4M, and free cash flow of -$336.2M (+7.6% YoY). On the balance sheet, IOVA closed FY2025 with $913.2M in total assets against $96.6M in total debt (Altman Z-Score: 7.08, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $263.5M | -$391.0M | -$302.4M | -$336.2M | $913.2M | $96.6M |
| FY2024 (FY) | 2024-12-31 | $164.1M | -$372.2M | -$353.0M | -$364.0M | $910.4M | $90.0M |
| FY2023 (FY) | 2023-12-31 | $1.2M | -$444.0M | -$361.8M | -$361.9M | $2.38B | $557.3M |
As of 2026-11-03, Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.02 (-5.42% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IOVA ranks #298 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IOVA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 34.3%, and ROIC of -35.0%. By comparison, TARS (Tarsus Pharmaceuticals Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -24.1%, cap $3.61B) and RLAY (Relay Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.79B). Among the 5-stock peer group, IOVA leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per IOVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425205), Iovance Biotherapeutics Inc. generated $263.5M in revenue (+60.6% YoY), -$391.0M in net income, and -$336.2M in free cash flow against $913.2M in total assets and $96.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
IOVA last traded at $8.02 (-5.42% on volume of 21,047,700 shares), positioning the stock -29.83% below its 50-day simple moving average ($11.43) and +34.34% above its 200-day simple moving average ($5.97). Across its 52-week range of $1.76 to $15.37, IOVA sits at the 46.0% percentile with a 14-day RSI of 31.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($7.02 to $9.02).
Iovance Biotherapeutics Inc. (IOVA) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $8.02 (-5.42% 1D, market capitalization $3.63B).
Iovance Biotherapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Reported revenue rose from $1.2M in FY 2023 to $164.1M in FY 2024 and $263.5M in FY 2025 but the source does not identify the sources of that revenue.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Iovance Biotherapeutics Inc. (IOVA) reported $263.5M in annual revenue (up from $164.1M in FY2024, +60.6% YoY) and -$391.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.2M revenue, -$444.0M net income) through FY2025, IOVA scaled operating cash flow to -$302.4M and free cash flow to -$336.2M, backed by $913.2M in total assets against $96.6M in total debt.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), IOVA carries a macro regime beta of 0.99 and gross margin of 34.3%.
Real-time company headlines, analyst actions, and sector developments for Iovance Biotherapeutics Inc. (IOVA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Iovance Biotherapeutics Inc. (IOVA) market action, institutional positioning, and fundamental catalysts.
Long IOVA at $8.48 targeting $10.68. Balance sheet strength (Altman Z 7.08, Debt/Equity 0.13) and reported revenue growth to $263.5M in FY 2025 give the company a financial base to work from.. Institutional whale score is 9/20 and the risk/reward vs. the $1.64 52-week low is skewed heavily in favor of bulls.
@ForensicBear Shorting a 9/20 institutional whale-flow stock at $8.48 is dangerous when funds are rotating into Health Care.
Fading this rally in IOVA at $8.48. Operating losses of -$403.4M in FY 2025, ROIC of -35%, and an RQD Insider Conviction score of 5/20 point to weak fundamentals and limited insider confidence.. With a beta of 0.99 and the stock sitting at $8.48 (52-wk range $1.64–$15.37), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: